IVA — Inventiva SA Share News
0.000.00%
Last trade - 00:00- €669.85m
- €502.00m
- €4.48m
Brief: Inventiva H1 Net Income EUR -175.882 Mln
Brief: Inventiva H1 Revenue EUR 4.5 Million
Brief: Inventiva Gets $10 Mln Milestone Payment From CTTQ
Brief: Inventiva Publishes Phase 2b Native Lanifibranor Results
Brief: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Brief: Inventiva SA Reports No Revenues For Q1 2025
Brief: Inventiva SA - Maximum Repurchase Price Set At 40 Euros Per Share
Brief: Inventiva Secures Second Tranche Under Structured Financing Of Max. EUR 348 Mln
Brief: Inventiva Says Topline Results From NATiV3 Expected In Second Half Of 2026
Brief: Inventiva Reports Its 2024 Full Year Results And Provides A Business Update
Brief: Inventiva SA - To Focus On Lanifibranor, Stop Preclinical Research, Reduce Workforce By 50%
Brief: Inventiva Secures EUR 21.4 Mln, Seals First Tranche Of Multi-Tranche Financing
Brief: Inventiva Posts 9-Month Revenues Of EUR 1.3 Million
Brief: Inventiva Reports 2024 Third Quarter Financial Information
Brief: Inventiva SA Says Legend Achieves Primary Efficacy Endpoint In Lowering Hba1c
Brief: Inventiva Says Positive Recommendation Of The Fifth DMC Of The Nativ3 Phase 3 Clinical Trial With Lanifibranor In Patients With Mash
Brief: Inventiva Announces Late Breaker Abstract From Mid-Stage Trial Evaluating lanifibranor In Combination With empagliflozin
Brief: Inventiva Announces Financing Of Up To €348 Million To Advance The Nativ3 Phase 3 Mash Study
Brief: Inventiva Provides An Update On Its NATiV3 Clinical Program Evaluating Lanifibranor In Patients With MASH/NASH And Its Financial Position